{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:11:03Z","timestamp":1789125063437,"version":"build-2803163510"},"reference-count":32,"publisher":"Bioscientifica","issue":"5","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Oxytocin (OXT) is known for its role in regulating social behavior, such as emotion recognition and bonding. The evidence for clinically relevant OXT deficiency is constantly increasing, but the measurement of OXT is challenging. In contrast, neurophysin-I (NP-I), the carrier protein of OXT and co-released equimolarly, is a stable surrogate biomarker for OXT. This study evaluated OXT and NP-I levels upon four different pituitary provocation tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Secondary analysis of four interventional diagnostic trials at the University Hospital Basel, Switzerland.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Sixty-six participants underwent a pituitary provocation test, 11 the hypertonic saline test, 20 the arginine infusion test, 25 the oral macimorelin test, and 10 the glucagon injection test. Plasma NP-I and OXT were measured at baseline and once the plasma sodium level reached \u2265150 mmol\/L for the hypertonic saline, after 60 min for the arginine infusion, after 60, 120, and 180 min for the glucagon injection, and after 45 min for the oral macimorelin test. The primary outcome was change from baseline to maximally stimulated NP-I levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median (IQR) NP-I plasma levels increased minimally in response to hypertonic saline (baseline: 55 pM, stimulated: 59 pM, relative median change of \u22128% (\u221216, +9)) and significantly to glucagon injection (baseline: 82 pM, stimulated: 94 pM, relative median change of +18% (+7, +28)). Median OXT levels showed similar trends in response to hypertonic saline (baseline: 0.36 pg\/mL (0.27, 0.45), stimulated: 0.48 pg\/mL (0.43, 0.59), relative median change of +22% (\u221215, +96)) and to glucagon injection (baseline: 82.7 pg\/mL (62.3, 94.3), stimulated: 93.4 pg\/mL (87.2, 121), relative median change of +25% (+6, +59). Neither the NP-I plasma levels nor OXT levels increased upon arginine infusion and oral macimorelin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NP-I showed minimal responses to pituitary provocation tests, paralleling OXT dynamics. These findings highlight NP-I\u2019s potential as a reliable and technically robust surrogate biomarker for OXT activity, warranting further evaluation in clinical and experimental settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/ec-25-0929","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:34:50Z","timestamp":1777289690000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":1,"title":["Neurophysin-I dynamics upon different pituitary provocation tests in healthy participants"],"prefix":"10.1530","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2294-9262","authenticated-orcid":true,"given":"Andi","family":"Nikaj","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland 1"},{"name":"Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5442-7304","authenticated-orcid":true,"given":"Cihan","family":"Atila","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland 1"},{"name":"Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Rudin","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology and Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland 3"},{"name":"Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0874-4875","authenticated-orcid":false,"given":"Dino","family":"Luethi","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology and Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland 3"},{"name":"Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6439-8191","authenticated-orcid":false,"given":"Clara O","family":"Sailer","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland 1"},{"name":"Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland 2"},{"name":"Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts, USA 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Winzeler","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland 1"},{"name":"Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland 2"},{"name":"Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich, Zurich, Switzerland 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4056-2262","authenticated-orcid":false,"given":"Sandrine A","family":"Urwyler","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland 1"},{"name":"Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3040-4685","authenticated-orcid":false,"given":"Julie","family":"Refardt","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland 1"},{"name":"Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland 2"},{"name":"Department of Internal Medicine, Section of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands 7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1765-9659","authenticated-orcid":true,"given":"Matthias E","family":"Liechti","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland 2"},{"name":"Division of Clinical Pharmacology and Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland 3"},{"name":"Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Christ-Crain","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland 1"},{"name":"Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland 2"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"2026091106562750900_bib1","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/j.2040-4603.2016.tb00727.x","article-title":"Magnocellular neurons and posterior pituitary function","volume":"6","author":"Brown","year":"2016","journal-title":"Compr Physiol"},{"key":"2026091106562750900_bib2","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1124\/pr.120.019398","article-title":"Is oxytocin \u201cnature\u2019s medicine\u201d?","volume":"72","author":"Carter","year":"2020","journal-title":"Pharmacol Rev"},{"key":"2026091106562750900_bib3","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S2213-8587(22)00219-4","article-title":"Central diabetes insipidus from a patient's perspective: management, psychological co-morbidities, and renaming of the condition: results from an international web-based survey","volume":"10","author":"Atila","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026091106562750900_bib4","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/ejendo\/lvae040","article-title":"Psychopathological characteristics in patients with arginine vasopressin deficiency (central diabetes insipidus) and primary polydipsia compared to healthy controls","volume":"190","author":"Atila","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"2026091106562750900_bib5","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S2213-8587(23)00120-1","article-title":"Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial","volume":"11","author":"Atila","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026091106562750900_bib6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41380-022-01719-z","article-title":"Advances in human oxytocin measurement: challenges and proposed solutions","volume":"28","author":"Tabak","year":"2023","journal-title":"Mol Psychiatry"},{"key":"2026091106562750900_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2021.105368","article-title":"Specificity of plasma oxytocin immunoassays: a comparison of commercial assays and sample preparation techniques using oxytocin knockout and wildtype mice","volume":"132","author":"Gnanadesikan","year":"2021","journal-title":"Psychoneuroendocrinology"},{"key":"2026091106562750900_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2022.105827","article-title":"What are oxytocin assays measuring? Epitope mapping, metabolites, and comparisons of wildtype & knockout mouse urine","volume":"143","author":"Gnanadesikan","year":"2022","journal-title":"Psychoneuroendocrinology"},{"key":"2026091106562750900_bib9","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/ejendo\/lvaf078","article-title":"Neurophysin I: a reliable, novel, and robust biomarker for oxytocin","volume":"192","author":"Atila","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"2026091106562750900_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2023.106951","article-title":"Neurophysin I is an analytically robust surrogate biomarker for oxytocin","volume":"161","author":"MacLean","year":"2024","journal-title":"Psychoneuroendocrinology"},{"key":"2026091106562750900_bib11","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41386-025-02248-3","article-title":"Acute effects of MDMA, MDA, lysine-MDMA, and lysine-MDA in a randomized, double-blind, placebo-controlled, crossover trial in healthy participants","volume":"51","author":"Straumann","year":"2025","journal-title":"Neuropsychopharmacology"},{"key":"2026091106562750900_bib12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/EJE-21-0346","article-title":"Oxytocin levels in response to pituitary provocation tests in healthy volunteers","volume":"185","author":"Sailer","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"2026091106562750900_bib13","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s12020-024-03920-2","article-title":"Plasma oxytocin levels in response to glucagon in patients with arginine vasopressin deficiency (central diabetes insipidus) and healthy controls","volume":"86","author":"Atila","year":"2024","journal-title":"Endocrine"},{"key":"2026091106562750900_bib14","doi-asserted-by":"crossref","first-page":"K24","DOI":"10.1093\/ejendo\/lvaf001","article-title":"Sex-dependent increases in oxytocin levels in response to intravenous kisspeptin in humans","volume":"192","author":"Galbiati","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"2026091106562750900_bib15","doi-asserted-by":"crossref","first-page":"e4205","DOI":"10.1210\/clinem\/dgaf201","article-title":"Melatonin as a possible stimulus to unmask an oxytocin-deficient state in hypopituitarism and hypothalamic damage","volume":"110","author":"Asla","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026091106562750900_bib16","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1210\/jc.2017-01891","article-title":"Release and decay kinetics of copeptin vs AVP in response to osmotic alterations in healthy volunteers","volume":"103","author":"Fenske","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2026091106562750900_bib17","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0140-6736(19)31255-3","article-title":"Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study","volume":"394","author":"Winzeler","year":"2019","journal-title":"Lancet"},{"key":"2026091106562750900_bib18","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s11102-021-01132-9","article-title":"Effects of oral macimorelin on copeptin and anterior pituitary hormones in healthy volunteers","volume":"24","author":"Urwyler","year":"2021","journal-title":"Pituitary"},{"key":"2026091106562750900_bib19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1530\/EJE-22-0033","article-title":"Glucagon-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a double-blind, randomized, placebo-controlled study","volume":"187","author":"Atila","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"2026091106562750900_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/jne.12413","article-title":"Measuring oxytocin and vasopressin: bioassays, immunoassays and random numbers","volume":"28","author":"Leng","year":"2016","journal-title":"J Neuroendocrinol"},{"key":"2026091106562750900_bib21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.psyneuen.2019.05.018","article-title":"Challenges for measuring oxytocin: the blind men and the elephant?","volume":"107","author":"MacLean","year":"2019","journal-title":"Psychoneuroendocrinology"},{"key":"2026091106562750900_bib22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/dta.2475","article-title":"Oxytocin analysis from human serum, urine, and saliva by orbitrap liquid chromatography-mass spectrometry","volume":"11","author":"Franke","year":"2019","journal-title":"Drug Test Anal"},{"key":"2026091106562750900_bib23","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1210\/jc.2006-2046","article-title":"Anterior and posterior pituitary function testing with simultaneous insulin tolerance test and a novel copeptin assay","volume":"92","author":"Katan","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2026091106562750900_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577446","article-title":"Interleukin-6 response to insulin-induced hypoglycemia is associated with hypothalamic-pituitary-adrenal axis activation","volume":"350","author":"Drummond","year":"2021","journal-title":"J Neuroimmunol"},{"key":"2026091106562750900_bib25","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/0026-0495(91)90220-Q","article-title":"Effect of estrogen or insulin-induced hypoglycemia on plasma oxytocin levels in bulimia and anorexia nervosa","volume":"40","author":"Chiodera","year":"1991","journal-title":"Metabolism"},{"key":"2026091106562750900_bib26","first-page":"655","article-title":"Hypoglycemia-induced arginine vasopressin and oxytocin release is mediated by glucoreceptors located inside the blood-brain barrier","volume":"55","author":"Chiodera","year":"1992","journal-title":"Neuroendocrinology"},{"key":"2026091106562750900_bib27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000506638","article-title":"Lower oxytocin levels are associated with lower bone mineral density and less favorable hip geometry in hypopituitary men","volume":"111","author":"Aulinas","year":"2021","journal-title":"Neuroendocrinology"},{"key":"2026091106562750900_bib28","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1210\/jc.2018-02608","article-title":"Low plasma oxytocin levels and increased psychopathology in hypopituitary men with diabetes insipidus","volume":"104","author":"Aulinas","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2026091106562750900_bib29","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1210\/endrev\/bnaf008","article-title":"The oxytocin system and implications for oxytocin deficiency in hypothalamic-pituitary disease","volume":"46","author":"Aulinas","year":"2025","journal-title":"Endocr Rev"},{"key":"2026091106562750900_bib30","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.4088\/JCP.10m06617","article-title":"Decreased nocturnal oxytocin levels in anorexia nervosa are associated with low bone mineral density and fat mass","volume":"72","author":"Lawson","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"2026091106562750900_bib31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1148\/radiology.143.1.7063747","article-title":"The meaning and use of the area under a receiver operating characteristic (ROC) curve","volume":"143","author":"Hanley","year":"1982","journal-title":"Radiology"},{"key":"2026091106562750900_bib32","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1210\/endo-98-2-468","article-title":"Plasma neurophysin levels in monkeys: emphasis on the hypothalamic response to estrogen and ovarian events","volume":"98","author":"Robinson","year":"1976","journal-title":"Endocrinology"}],"container-title":["Endocrine Connections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/15\/5\/EC-25-0929.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/15\/5\/EC-25-0929.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-25-0929\/504536\/ec-25-0929.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-25-0929\/504536\/ec-25-0929.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:56:37Z","timestamp":1789124197000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article\/15\/5\/e250929\/75428\/Neurophysin-I-dynamics-upon-different-pituitary"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1530\/ec-25-0929","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"article-number":"e250929"}}